University of Texas System

Other

Otc Technologies, LLC

Kenneth Michael Hargreaves

John G Bruno

Armen Norakovich Akopian

Amol Madhusudan Patwardhan

Anibal Diogenes

A method for treating and/or diagnosing pain and the source or type of pain, shock, and/or inflammatory conditions in a subject. A method of using a therapeutically effective amount of a DNA or RNA aptamer that shows high affinity for OLAMs to at least partially treat pain, shock, and/or inflammatory conditions in a subject. The DNA or RNA aptamer that shows high affinity for OLAMs may be coupled to a plasma protein binding compound or a pharmacologically active agent. A method of treating and or diagnosing pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation) using a DNA or RNA aptamer that shows high affinity for OLAMs.

Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof

A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

Family of pain producing substances and methods to produce novel analgesic drugs

The embodiments disclosed herein provide methods for inhibiting, reducing and/or treating pain in a subject by administering to a subject in need thereof a pharmaceutical formulation that includes a pharmacologically active compound that is adapted to disrupt PRL signaling in pain neurons. In certain embodiments, the compound is a PRL-R antagonist. In certain embodiments, the compound is adapted to alter the expression of one or more components involved in PRL signaling. Also provided for herein are methods to diagnose a pain disorder in a subject, comprising obtaining a measure of the amount of PRL or PRL mRNA in a biological sample.

Growing community of inventors

San Antonio, TX, United States of America

Kenneth Michael Hargreaves